Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple
combination with protease inhibitor is recommended. Such therapy induces side effects and the
number of pills may reduce therapy adherence. The aim of this study is to evaluate the
efficacy and the safety of a once daily FTC, ddI, efavirenz combination, in HIV patients with
CD4 cell count over 100/mm3, antiretroviral naive.
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis